Sir,
A 79-year-old woman with deep vein thrombosis was referred for evaluation of the source of the obscure gastrointestinal bleeding by capsule endoscopy (CE) before anticoagulant therapy. She had iron deficiency anemia, which necessitated transfusions (approximately 2 units per month). Her hemoglobin level was 82 mg/L, whereas her mean corpuscular volume was 72 fL. The results of the investigations for the source of the obscure gastrointestinal bleeding were negative, including esophagogastroduodenoscopy and colonoscopy. Her past medical history included arrhythmia and atrioventricular block. A cardiac pacemaker (Biotronik, Talos DR, bipolar, DDDR mode, Germany) was inserted, due to atrioventricular block, about two and a half years ago. We did not observe any adverse events when we carried out the CE procedure in our patient with implanted cardiac pacemaker. In addıtıon, we did not find any technical abnormalities or interference with the capsule endoscopic images.
The US Food and Drug Administration and the manufacturers, Given Imaging and Olympus, recommend not to use CE in patients with cardiac pacemakers and implantable cardioverter defibrillators (ICDs).
[1] Several studies and case reports about interference between pacemakers and ICDs have been published. [1] [2] [3] [4] Interference between CE and telemetry (eg, artifacts, impossibility to document CE images) has been reported to occur in two cases in a retrospective study. [2] Furthermore, CE appears to be safe in patients with pacemakers or ICDs without the use of telemetry. [3] No adverse events were found in any of the two patients (one adult and one pediatric patient) with abdominal pacemakers during CE. [4] CE was performed for obscure gastrointestinal bleeding in 97% of the patients with a pacemaker and in all patients with ICDs. [1] In our experience and based on the literature, the clinical use of CE appears to be safe in patients with cardiac pacemaker or ICDs.
Helicobacter Pylori in the Era of Probiotics: A Controversial Application
Sir, Owing to the increased rate of resistance among the Helicobacter pylori strains, the efficacy of the prescribed antibiotics has reduced globally. [1] Consequently, alternative approaches can be an option to overcome this unsolved issue in clinical trials. [2] Probiotics, as a living bacterium in gastrointestinal routes, which provides health benefits has been called as a potential candidate. Recently, several studies investigated the efficacy of different probiotics in experimental and large scale levels. Recently, Dajani et al., proposed Bifidobacterium infantis as a preferable adjuvant for several therapeutic regimens used to eradicate the H. pylori infection. [3] Although probiotic therapy as an adjuvant had been reported to be an effective approach for treatment of H. pylori, the exact mechanism is not clearly elucidated yet. Moreover, the success of each of the three investigated therapeutic regimens in study by Dajani et al., need to be evaluated separately. [2] In other words, prescription of 
